Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Context Therapeutics Inc.

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Two April 2023 Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.